Newamsterdam Pharma Company N.V. (NAMS) Stock Price, Quote & News

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

8869scy Jul. 25 at 10:35 PM

$NAMS heavy mid 20s puts for August, not one but now two top executives leaving in August, and heavy continuous insider selling with zero buying has kept me from adding more. I am bullish but can't ignore the above.

1 · Reply

CH_Expat Jul. 25 at 5:40 PM

$NAMS Probs to @masonat. Legend. Helped me big time on my DD.

1 · Reply

masonat Jul. 24 at 1:29 PM

$NAMS Very close now! Side note, I hope the brand names in US are better

0 · Reply

Gan1729 Jul. 24 at 1:28 PM

$NAMS https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-and-menarini-group-receive-positive-chmp

0 · Reply

masonat Jul. 22 at 6:21 PM

$NAMS Potential catalysts in the next six months: - EMA approval, Aug-October? - HORIZON readout, 2H 2026 - RUBENS readout, EOY - PREVAIL readout, ~January 2027 Ranked by my expected impact on stock price: PREVAIL >>> HORIZON > EMA > RUBENS

0 · Reply